NO20025635L - Anvendelse av biguanidderivater til fremstilling av et legemiddel som har en sarhelende virkning - Google Patents

Anvendelse av biguanidderivater til fremstilling av et legemiddel som har en sarhelende virkning

Info

Publication number
NO20025635L
NO20025635L NO20025635A NO20025635A NO20025635L NO 20025635 L NO20025635 L NO 20025635L NO 20025635 A NO20025635 A NO 20025635A NO 20025635 A NO20025635 A NO 20025635A NO 20025635 L NO20025635 L NO 20025635L
Authority
NO
Norway
Prior art keywords
drug
preparation
curative effect
biguanide derivatives
biguanide
Prior art date
Application number
NO20025635A
Other languages
English (en)
Norwegian (no)
Other versions
NO20025635D0 (no
Inventor
Pierre Jean-Paul Potier
Nobumichi-Andre Sasaki
Achib Maria Conception I
Gisele Franck
Claude Thal
Joanna Bakala
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8850685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20025635(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Publication of NO20025635D0 publication Critical patent/NO20025635D0/no
Publication of NO20025635L publication Critical patent/NO20025635L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20025635A 2000-05-26 2002-11-22 Anvendelse av biguanidderivater til fremstilling av et legemiddel som har en sarhelende virkning NO20025635L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0006798A FR2809310B1 (fr) 2000-05-26 2000-05-26 Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
PCT/FR2001/001598 WO2001091696A2 (fr) 2000-05-26 2001-05-23 Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant

Publications (2)

Publication Number Publication Date
NO20025635D0 NO20025635D0 (no) 2002-11-22
NO20025635L true NO20025635L (no) 2003-01-21

Family

ID=8850685

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20025635A NO20025635L (no) 2000-05-26 2002-11-22 Anvendelse av biguanidderivater til fremstilling av et legemiddel som har en sarhelende virkning

Country Status (25)

Country Link
US (1) US7199159B2 (sk)
EP (1) EP1283708B1 (sk)
JP (1) JP4987209B2 (sk)
KR (1) KR20030029050A (sk)
CN (1) CN100420439C (sk)
AR (1) AR032617A1 (sk)
AT (1) ATE300942T1 (sk)
AU (2) AU6401101A (sk)
BG (1) BG65847B1 (sk)
BR (1) BRPI0111142C1 (sk)
CA (1) CA2410025C (sk)
DE (1) DE60112431T2 (sk)
DK (1) DK1283708T3 (sk)
EC (1) ECSP024359A (sk)
EE (1) EE05393B1 (sk)
ES (1) ES2244625T3 (sk)
FR (1) FR2809310B1 (sk)
HU (1) HU229205B1 (sk)
MX (1) MXPA02011622A (sk)
MY (1) MY137468A (sk)
NO (1) NO20025635L (sk)
PT (1) PT1283708E (sk)
SK (1) SK287249B6 (sk)
UA (1) UA76415C2 (sk)
WO (1) WO2001091696A2 (sk)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2858232B1 (fr) * 2003-07-29 2006-03-03 Pierre Potier Utilisation d'un derive de biguanide pour proteger la peau des radiations uvb
DE102004022645A1 (de) * 2004-05-07 2005-12-15 Resorba Wundversorgung Gmbh & Co. Kg Bioresorbierbares Material auf Kollagen-Basis
JP4877456B2 (ja) * 2005-04-14 2012-02-15 株式会社 メドレックス ビグアナイド系薬剤を含有するゼリー製剤
CN105152983A (zh) * 2007-01-29 2015-12-16 韩诺生物制药株式会社 N,n-二甲基亚氨基二碳亚氨酸二酰胺乙酸盐、其制备方法和包含其的药物组合物
EP2321425A1 (en) * 2008-08-28 2011-05-18 Tyco Healthcare Group LP Carrier neutralization/modification in antimicrobial compositions, articles and methods
WO2011083998A2 (ko) 2010-01-06 2011-07-14 한올바이오파마주식회사 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
DE212011100215U1 (de) 2011-07-22 2014-03-05 Karel Paul Bouter Ernährungsprodukt, umfassend ein Biguanid
KR101425061B1 (ko) * 2011-08-08 2014-08-06 한올바이오파마주식회사 Ν1-고리아민-ν5-치환된 페닐 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
WO2013022280A2 (en) * 2011-08-08 2013-02-14 Hanall Biopharma Co., Ltd. N1-cyclic amine-n2-substituted biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
KR101486865B1 (ko) 2011-08-08 2015-01-30 한올바이오파마주식회사 Ｎ1-고리아민-ｎ5-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물
CN106458868A (zh) 2014-04-17 2017-02-22 伊谬诺米特医疗有限公司 胍化合物及其用途
CN104262205B (zh) * 2014-09-02 2017-04-12 浙江工业大学 N‑芳基双胍氢碘酸盐类化合物及其制备方法和应用
KR102216701B1 (ko) 2014-11-20 2021-02-18 이뮤노메트테라퓨틱스 인코포레이티드 바이구아나이드 화합물 및 이의 용도
FR3035787B1 (fr) 2015-05-07 2018-08-24 L'oreal Procede de traitement des matieres keratiniques a partir de derives de c-glycosides amides, acides ou ester, et la composition cosmetique les contenant
FR3053892A1 (fr) 2016-07-12 2018-01-19 Urgo Recherche Innovation Et Developpement Pansement permettant la liberation controlee et prolongee de la metformine
CN106822075A (zh) * 2017-03-31 2017-06-13 浙江萧山医院 二甲双胍在促进伤口愈合中的应用
FR3068974B1 (fr) 2017-07-12 2019-08-02 Urgo Recherche Innovation Et Developpement Pansement permettant la liberation controlee et prolongee d'actif
FR3088542B1 (fr) 2018-11-21 2021-03-19 Waterdiam France Sas Composition cicatrisante comprenant une eau électrolysée
CN110179776B (zh) * 2019-05-31 2022-09-06 宁夏医科大学 二甲双胍的新用途与二甲双胍组合物及组合物的制备方法和应用
CN112494469A (zh) * 2020-07-30 2021-03-16 吴学雷 二甲双胍在制备预防和/或治疗瘢痕的药物中的应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB852584A (en) 1956-05-31 1960-10-26 Us Vitamin Corp Biguanide compositions
US2961377A (en) 1957-08-05 1960-11-22 Us Vitamin Pharm Corp Oral anti-diabetic compositions and methods
US3098008A (en) * 1960-10-05 1963-07-16 Us Vitamin Pharm Corp Method for treatment of dermatological disorders
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3468898A (en) 1966-05-26 1969-09-23 Sterling Drug Inc Bridged bis-biguanides and bis-guanidines
US3996232A (en) * 1970-11-23 1976-12-07 William H. Rorer, Inc. 1,5-Disubstituted biguanides
GB1351025A (en) 1971-08-20 1974-04-24 Aron Md Samuel J Oxadiazol-5-yl biguanide derivatives method for their preparation and pharmaceutical compositions containing them
US3852353A (en) 1972-12-12 1974-12-03 C Heaphy Oral hypoglycemic aminophenylsulfonyl-hydrocarbylbiguanides
US3929999A (en) 1972-12-12 1975-12-30 Clifford John Heaphy Oral hypoglycemic method
DE2401450A1 (de) * 1973-01-16 1974-07-18 John James Voorhees Pharmazeutische zusammensetzung zur linderung von hautproliferationserkrankungen
US4211770A (en) * 1973-01-16 1980-07-08 The Upjohn Company Treatment of psoriasis intralesionally with N6 -2'-O-dibutyryl cyclic AMP
CH602612A5 (sk) 1974-10-11 1978-07-31 Hoffmann La Roche
FR2320735A1 (fr) * 1975-08-12 1977-03-11 Dabis Georges Composition anti-cellulite
US4163800A (en) * 1977-08-17 1979-08-07 The Procter & Gamble Company Topical composition and treatment of skin lesions therewith
NZ207147A (en) 1983-02-28 1987-08-31 Johnson & Johnson Prod Inc Adhesive bandage containing medicinal substance: pad and base prepared from bulky, non-woven material
FR2552305B1 (fr) * 1983-09-22 1985-12-20 Salkin Andre Composition a pouvoir bactericide eleve contenant un biguanide et une pyrimidine
FR2585572B3 (fr) 1985-07-31 1987-12-31 Hugelin Andre Nouvelles compositions pharmaceutiques a base d'un sel de l'acide p. chlorophenoxyacetique destinees au traitement des neuropathies et assurant la regeneration nerveuse
FR2611500B1 (fr) * 1987-03-06 1990-05-04 Lipha Emploi de derives du biguanide dans la preparation de medicaments
AU1834188A (en) 1987-06-29 1989-01-05 Kendall Company, The Novel medicated dressings
US5246708A (en) 1987-10-28 1993-09-21 Pro-Neuron, Inc. Methods for promoting wound healing with deoxyribonucleosides
SU1560212A1 (ru) * 1988-11-10 1990-04-30 Киевский Медицинский Институт Им.Акад.А.А.Богомольца Способ лечени сифилиса
IT1241994B (it) 1990-08-30 1994-02-02 Idi Farmaceutici Composizione farmaceutica ad effetto cicatrizzante.
IL97771A (en) * 1991-04-04 1996-12-05 Sion Narrow Weaving Dry polymeric material having antimicrobial activity
IT1249711B (it) * 1991-09-30 1995-03-09 Boniscontro E Gazzone S R L Composizioni farmaceutiche, per uso topico, contenenti "scavengers" di radicali liberi dell'ossigeno e antibatterici,indicate nella terapia dei tessuti superficiali.
IT1256111B (it) * 1992-11-23 1995-11-28 Lifegroup Spa Sali dell'acido traumatico ad attivita' cicatrizzante ed antibatterica
JP3493692B2 (ja) 1993-09-09 2004-02-03 三菱マテリアル株式会社 ビスビグアナイド系化合物およびそれを含む殺菌剤
DE19503336C2 (de) * 1995-02-02 1998-07-30 Lohmann Therapie Syst Lts Arzneiform zur Abgabe von Wirkstoffen an Wunden, Verfahren zu ihrer Herstellung und ihre Verwendung
US5747527A (en) * 1995-06-06 1998-05-05 Shaman Pharmaceuticals, Inc. Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
US5668084A (en) 1995-08-01 1997-09-16 Zeneca Inc. Polyhexamethylene biguanide and surfactant composition and method for preventing waterline residue
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US5827898A (en) * 1996-10-07 1998-10-27 Shaman Pharmaceuticals, Inc. Use of bisphenolic compounds to treat type II diabetes
US5837255A (en) * 1996-12-10 1998-11-17 Shaman Pharmaceuticals, Inc. Method of reducing blood glucose by administering Harunganin or Vismin
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US5811078A (en) * 1997-03-14 1998-09-22 Adolor Corporation Spray formulations of antihyperalgesic opiates and method of treating topical hyperalgesic conditions therewith
JP3054758B2 (ja) * 1997-03-27 2000-06-19 小林製薬株式会社 外傷用組成物
CN1197643A (zh) * 1997-04-30 1998-11-04 谢瑞钢 一种创伤油膏
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
BR9813826A (pt) * 1997-12-22 2000-10-10 Euro Celtique Sa Potencial de uso abusivo de administração oral de opióide analgésico
BR9912395A (pt) * 1998-07-24 2001-10-16 Seo Hong Yoo Preparação de formas de dosagem de solução clara aquosa com ácidos biliares
WO2000033829A1 (de) 1998-12-05 2000-06-15 Fresenius Kabi Deutschland Gmbh Verwendung von poly (hexamethylen) biguanid zur herstellung eines mittels zur förderung der heilung von infektionsfreien wunden
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CO5200844A1 (es) 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
WO2001062237A2 (en) * 2000-02-23 2001-08-30 Orentreich Foundation For The Advancement Of Science, Inc. Compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
ATE266409T1 (de) * 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone

Also Published As

Publication number Publication date
BG107304A (bg) 2003-06-30
WO2001091696A8 (fr) 2003-01-09
CN1635880A (zh) 2005-07-06
SK16582002A3 (sk) 2003-04-01
FR2809310A1 (fr) 2001-11-30
MXPA02011622A (es) 2003-03-27
CA2410025C (fr) 2011-09-06
PT1283708E (pt) 2005-11-30
EE200200657A (et) 2004-06-15
MY137468A (en) 2009-01-30
WO2001091696A3 (fr) 2002-06-06
CA2410025A1 (fr) 2001-12-06
HUP0302038A3 (en) 2009-08-28
US7199159B2 (en) 2007-04-03
NO20025635D0 (no) 2002-11-22
ECSP024359A (es) 2004-03-23
BRPI0111142B1 (pt) 2017-10-24
SK287249B6 (sk) 2010-04-07
DK1283708T3 (da) 2005-12-27
CN100420439C (zh) 2008-09-24
AU2001264011B2 (en) 2005-09-15
ATE300942T1 (de) 2005-08-15
EP1283708A2 (fr) 2003-02-19
KR20030029050A (ko) 2003-04-11
JP4987209B2 (ja) 2012-07-25
BR0111142A (pt) 2003-04-08
PL359063A1 (en) 2004-08-23
ES2244625T3 (es) 2005-12-16
BG65847B1 (bg) 2010-03-31
AR032617A1 (es) 2003-11-19
UA76415C2 (uk) 2006-08-15
WO2001091696A2 (fr) 2001-12-06
HU229205B1 (en) 2013-09-30
JP2003534359A (ja) 2003-11-18
BRPI0111142C1 (pt) 2021-05-25
EP1283708B1 (fr) 2005-08-03
US20030187036A1 (en) 2003-10-02
EE05393B1 (et) 2011-04-15
FR2809310B1 (fr) 2004-02-13
HUP0302038A2 (hu) 2003-09-29
AU6401101A (en) 2001-12-11
BRPI0111142B8 (pt) 2018-05-02
DE60112431D1 (de) 2005-09-08
DE60112431T2 (de) 2006-06-01

Similar Documents

Publication Publication Date Title
NO20025635L (no) Anvendelse av biguanidderivater til fremstilling av et legemiddel som har en sarhelende virkning
DK1207867T3 (da) Retarderede, orale farmaceutiske indgivelsesformer med tramadol
NO20025879L (no) Acylfenylureaderivater, fremgangsmåter for fremstilling derav og deres anvendelse som legemiddel
NO20043702L (no) 8-azaprostaglandinderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
DE50212546D1 (de) Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung
ITTO20010008A0 (it) Formulazione farmaceutica
NO20034149L (no) Legemidler inneholdende triazaspiro[5.5]undekanderivater som den aktive bestanddel
DK1498411T3 (da) Diketohydrazinderivatforbindelser og medikamenter indeholdende forbindelserne som den aktive bestanddel
NO20042807L (no) Farmasoytiske sammensetninger som innbefatter aktive vitamin D forbindelser
NO20021329L (no) Kinaseinhibitorer som terapeutiske midler
DK1397364T3 (da) Hidtil ukendte pyrrolderivater som farmaceutiske midler
DK2298769T3 (da) Xanthinderivater, deres fremstilling og deres anvendelse som lægemiddel
DK1307457T3 (da) Azabicycliske forbindelser, deres fremstilling og deres anvendelse som medikamenter, især som antibakterielle midler
DK1592457T3 (da) Folat-vinblastin-konjugat som lægemiddel
FIU20000164U0 (fi) Uusi farmaseuttinen formulaatio
NO20032926L (no) Heterocykliske forbindelser som har antibakteriell aktivitet, fremgangsmåtefor deres fremstilling og farmasöytiske sammensetninger sominneholder dem
DK1557415T3 (da) Heterocykliske forbindelser og antitumorlægemidler indeholdende samme som den aktive ingrediens
NO20044322L (no) Benzoksanon-avledede forbindelser, deres fremstilling og anvendelse som medikament
NO20054214D0 (no) Iminoeterderivatforbindelser og legemidler inneholdende forbindelsene som den aktive bestanddel
DK1453810T3 (da) Substituerede 4-phenyltetrahydroisoquinoliner, fremgangsmåde til deres fremstilling, deres anvendelse som medikament indeholdende samme
NO20024745L (no) 2-hydroksymutilinkarbamat-derivater for antibakteriell anvendelse
NO20030100D0 (no) Pleuromutilinderivater som har antibakteriell aktivitet
NO20032614L (no) Farmasöytisk sammensetning som har forbedret absorberbarhet
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
DE69907675D1 (de) Ein substituiertes triazolo-pyridazin-derivat, davon hergestellte arzneimittel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application